These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21691466)

  • 1. Genetics of warfarin sensitivity in an emergency department population with thromboembolic.
    Johnson SW; Henderson S
    West J Emerg Med; 2011 Feb; 12(1):11-6. PubMed ID: 21691466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
    Ruaño G; Thompson PD; Villagra D; Bower B; Kocherla M; Yazdanpanah G; Seip RL; Windemuth A; White CM; Duconge J; Holford TR; Wu AH
    Per Med; 2008 May; 5(3):225-232. PubMed ID: 29783498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
    Scott SA; Edelmann L; Kornreich R; Desnick RJ
    Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of
    Al-Eitan LN; Almasri AY; Khasawneh RH
    Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30486437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
    Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
    Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
    Hillman MA; Wilke RA; Yale SH; Vidaillet HJ; Caldwell MD; Glurich I; Berg RL; Schmelzer J; Burmester JK
    Clin Med Res; 2005 Aug; 3(3):137-45. PubMed ID: 16160068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy.
    Poopak B; Rabieipoor S; Safari N; Naraghi E; Sheikhsofla F; Khosravipoor G
    Int J Hematol Oncol Stem Cell Res; 2015 Oct; 9(4):185-92. PubMed ID: 26865929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
    Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
    J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
    Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
    J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
    French B; Joo J; Geller NL; Kimmel SE; Rosenberg Y; Anderson JL; Gage BF; Johnson JA; Ellenberg JH;
    Trials; 2010 Nov; 11():108. PubMed ID: 21083927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.